Exome Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Exome Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.01M	Buy	+215,376	New	+$3.57M	2.08%	16
2025 Q4	–	Sell	-178,084	Closed	-$1.28M	–	77
2025 Q3	$1.28M	Buy	+178,084	New	+$9.28M	0.77%	46
2024 Q1	–	Sell	-9,744	Closed	-$588K	–	66
2023 Q4	$588K	Buy	+9,744	New	+$502K	0.58%	46

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Exome Asset Management's MLTX Position: Q1 2026 in Review

Exome Asset Management opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 215,376 shares worth $4.01M. The stake represents 2.08% of the portfolio and ranks #16 among its holdings. This is a return to the name: Exome Asset Management previously reported a position in MLTX as recently as Q3 2025.

Exome Asset Management first reported a position in MLTX in Q4 2023 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Exome Asset Management held 215,376 shares of MoonLake Immunotherapeutics worth $4.01M as of Q1 2026.
MoonLake Immunotherapeutics was a new Exome Asset Management position in Q1 2026.
MoonLake Immunotherapeutics made up 2.08% of Exome Asset Management's portfolio in Q1 2026, its #16 holding.
Exome Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 3 quarters since.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.